An Open-label Prospective Noncomparative Clinical Study to Evaluate the Efficacy and Safety of Beliv: An Ayurvedic Medicine in Improving Liver Function

Simple item page
dc.contributor.authorSamudrala, Nareshen_US
dc.date.accessioned2023-08-09T06:14:08Z
dc.date.available2023-08-09T06:14:08Z
dc.date.issued2023-04
dc.description.abstractAn open-label prospective noncomparative study was conducted to examine the efficacy and safety of Beliv tablet, a polyherbal Ayurvedic medicine, in 30 adult patients suffering from liver disorders. Two tablets were administered daily for 56 days. Patients were evaluated at Day 0, Day 21, Day 42 and at Day 56. The primary end point of the study was a change in liver function test parameters measured by the levels of serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT) and total bilirubin at all assessment points. Results showed a significant reduction in the serum levels of SGOT, SGPT and total bilirubin from baseline to 21 days, 42 days and 56 days. The total icterus symptom score was also significantly reduced from 5.17 ± 2.26 (baseline) to 2.6 ± 1.48, 1.37 ± 1.13 and 0.77 ± 0.73 at Days 21, 42 and 56, respectively. The Subjective Global Assessment (SGA) decreased significantly from 3.33 ± 1.16 (Day 21) to 2.33 ± 1.16 and 1.80 ± 0.76 at Days 42 and 56, respectively. The Physician Global Assessment (PGA) score was also significantly reduced from 3.0 ± 1.02 (Day 21) to 2.07 ± 0.83 and 1.70 ± 0.79 at Days 42 and 56, respectively. A significant reduction in serum creatinine level was observed at Day 56. No adverse effects or serious adverse effects were observed during the study period. The study concluded that Beliv tablet was highly effective for the treatment of liver disorders, as evidenced by the reduction in serum levels of SGOT, SGPT, total bilirubin, icterus symptoms and PGA and SGA scores. No treatment-related side effects were reported by any of the study participants suggesting that it was safe for clinical use in humans for the treatment of liver disorders.en_US
dc.identifier.affiliationsFamily Physician and Diabetologist NP Anjali Poly Clinic & Day Care Center, Indira Nagar Raipura, Hanamkonda, Telangana E-mail: nani8369@gmail.comen_US
dc.identifier.citationSamudrala Naresh. An Open-label Prospective Noncomparative Clinical Study to Evaluate the Efficacy and Safety of Beliv: An Ayurvedic Medicine in Improving Liver Function. Indian Journal of Clinical Practice. 2023 Apr; 33(11): 26-36en_US
dc.identifier.issn0971-0876
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/222117
dc.languageenen_US
dc.publisherIJCP Groupen_US
dc.relation.issuenumber11en_US
dc.relation.volume33en_US
dc.source.urihttps://ijcp.in/Pages/Post_Detail.aspx?wid=20561&An%20Open-label%20Prospective%20Noncomparative%20Clinical%20Study%20to%20Evaluate%20the%20Efficacy%20and%20Safety%20of%20Beliv:%20An%20Ayurvedic%20Medicine%20in%20Improving%20Liver%20Functionen_US
dc.subjectLiver disordersen_US
dc.subjectliver function testsen_US
dc.subjectSGA scoreen_US
dc.subjectPGA scoreen_US
dc.subjecticterus symptom scoreen_US
dc.titleAn Open-label Prospective Noncomparative Clinical Study to Evaluate the Efficacy and Safety of Beliv: An Ayurvedic Medicine in Improving Liver Functionen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJCP2023v33n11p26.pdf
Size:
526.02 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Clinical Practice